Key Insights

Highlights

Success Rate

83% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

12.5%

2 terminated out of 16 trials

Success Rate

83.3%

-3.2% vs benchmark

Late-Stage Pipeline

13%

2 trials in Phase 3/4

Results Transparency

70%

7 of 10 completed with results

Key Signals

7 with results83% success

Data Visualizations

Phase Distribution

12Total
Not Applicable (2)
P 1 (2)
P 2 (6)
P 3 (2)

Trial Status

Completed10
Terminated2
Recruiting2
Enrolling By Invitation1
Withdrawn1

Trial Success Rate

83.3%

Benchmark: 86.5%

Based on 10 completed trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT06330324Enrolling By Invitation

Reproductive Options in Inherited Skin Diseases

NCT06330350Recruiting

Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling

NCT05463757Recruiting

Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study

NCT03467789Phase 1Completed

Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma

NCT04308395Phase 3TerminatedPrimary

Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)

NCT03703310Phase 3CompletedPrimary

Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)

NCT04416516Phase 2Completed

Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor

NCT00957229Phase 2CompletedPrimary

To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)

NCT01556009Phase 2CompletedPrimary

Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas

NCT02157623Not ApplicableCompletedPrimary

Blue vs Red Light During Levulan Based Photodynamic Therapy in Patients With Basal Cell Nevus Syndrome

NCT02762084Phase 2CompletedPrimary

Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients

NCT03767439Phase 2WithdrawnPrimary

Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome

NCT02303041Phase 2Terminated

Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma

NCT02550678Phase 1CompletedPrimary

A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma

NCT02100371Not ApplicableCompletedPrimary

Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome

NCT00555633Completed

Use of an SPF30 Sunscreen and an After-sun-lotion in Skin Cancer Risk Patients

Showing all 16 trials

Research Network

Activity Timeline